Document is current
Any future updates will be listed below
-
Authors
Chiaro, Jacopo
Peltonen, Karita
Õunap, Kadri
Bailey, Aubrey
Feola, Sara
Wojciechowski, Sara
Es-Haghi, Masoumeh
Azkargorta, Mikel
Elortza, Félix
Russo, Salvatore
Sallinen, Hanna
Anttila, Maarit
Gurvich, Olga
Cerullo, Vincenzo
Kekarainen, Tuija
-
Funding
Funding for this research was provided by:
Doctoral Programme in Drug Research (DPDR), Helsinki University
Suomen Kulttuurirahasto (00220190)
K. Albin Johanssons Stiftelse
GeneCellNano flagship
European Research Council (ERC), Horizon 2020 (681219)
Magnus Ehrnroothin Säätiö (4706235)
Jane ja Aatos Erkon Säätiö (4705796)
Syöpäsäätiö (4706116)
Helsinki Institute of Life Science, Helsingin Yliopisto (797011004)
Digital Precision Cancer Medicine Flagship iCAN
- License Information
-
More Information
Article History
Received: 6 March 2025
Accepted: 14 July 2025
First Online: 16 August 2025
Competing interests
: V.C. is co-founder and shareholder of Valo Therapeutics Oy. The other authors declare no competing interests.
